Etranacogene Dezaparvovec

Brand names: Hemgenix · Active ingredient: Etranacogene Dezaparvovec

In short: HEMGENIX is indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: Currently use Factor IX prophylaxis therapy, or Have current or historical life-threatening hemorrhage, or Have repeated, serious spontaneous bleeding episodes.

Forms & strengthsHEMGENIX is a clear and colorless suspension for intravenous infusion. HEMGENIX is provided in a kit containing 10 to 48 vials. Each kit constitutes a dosage unit based on the patient's body weight. …
LabelCSL Behring
Label updatedMay 11, 2026

What is Etranacogene Dezaparvovec used for?

HEMGENIX is indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:

Currently use Factor IX prophylaxis therapy, or

Have current or historical life-threatening hemorrhage, or

Have repeated, serious spontaneous bleeding episodes.

Etranacogene Dezaparvovec dosage

For single-use intravenous infusion only.

For patient selection:

Perform Factor IX inhibitor titer testing. Do not administer HEMGENIX for patients with positive FIX inhibitors or a prior history for FIX inhibitors.

Perform liver health assessments, including: Enzyme testing [alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bilirubin)], hepatic ultrasound and elastography. In case of radiological liver abnormalities and/or sustained liver enzyme elevations, consider a consultation with hepatologist to assess eligibility for HEMGENIX.

Perform laboratory tests to evaluate active hepatitis B and C. Postpone HEMGENIX treatment until patient does not have active hepatitis B or C infection as active infection may reduce the efficacy of HEMGENIX and/or increase the risk of adverse reactions .

The recommended dose of HEMGENIX is 2 × 1013 genome copies (gc) per kilogram (kg) of body weight (or 2 mL/kg body weight) administered as an intravenous infusion after dilution with 0.9% sodium chloride solution (normal saline) .

Calculate the dose as follows:

HEMGENIX dose (in mL) = patient body weight (in kilogram) × 2

The multiplication factor 2 represents the per kilogram dose (2 × 1013 gc/kg) divided by the amount of genome copies per mL of the HEMGENIX solution (1 × 1013 gc/mL).

Number of HEMGENIX vials needed = HEMGENIX dose (in mL) divided by 10 (round up to next whole number of vials).

The division factor 10 represents the extractable volume of HEMGENIX from each vial (10 mL).

The total volume of the patient's HEMGENIX dose to be diluted may be less than the total volume of vials needed.

Example calculation for 72 kg patient:

HEMGENIX dose (in ML) = 72 × 2 = 144 mL

Number of HEMGENIX vials needed = 144 (mL) / 10(mL per vial) = 14.4 vials = 15 Vials (rounded up)

HEMGENIX can be administered only once.

The vials are for single-dose only.

General precautions

Prepare HEMGENIX using sterile technique under aseptic conditions, proper engineering controls (e.g., biological safety cabinet or isolator) and according to institutional policies.

Do not expose HEMGENIX to the light of an ultraviolet radiation disinfection lamp.

Confirm that the patient's identity matches with the patient-specific identifier number on the outer carton.

Verify the required dose of HEMGENIX based on the patient's body weight.

Confirm that the carton contains sufficient number of vials to prepare the diluted HEMGENIX patient-specific infusion bag.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. …

How to take Etranacogene Dezaparvovec — instructions & advice from the label

Inform patients that:

Pre-infusion blood tests will be necessary to look for Factor IX inhibitors. If these exist, the patient is not a candidate for HEMGENIX .

Prior to HEMGENIX treatment, a liver ultrasound and elastography will be performed. Patients found to have pre-existing risk factors for hepatocellular carcinoma will be monitored annually in the 5 years following infusion .

Infusion-related and allergic reactions can occur. Patients will be monitored during and for at least 3 hours following administration. If a reaction occurs, the infusion rate may be slowed or interrupted, then started at a slower rate .

HEMGENIX can elevate certain liver enzymes. Weekly blood tests will be required to monitor for this for 3 months after treatment. Corticosteroid treatment may be necessary if this occurs .

If post-infusion bleeding is not controlled or if bleeding returns, then blood tests will be performed for Factor IX activity and neutralizing Factor IX inhibitors .

Vector distribution in blood (within the body), and vector shedding in semen and other excreta and secreta can occur post-infusion. It is not known how long this will continue. …

Warnings & precautions

Do not take this medicine if: None.

Moderate to severe hypersensitivity and infusion-related reactions have occurred with HEMGENIX treatment . Anaphylaxis may occur with HEMGENIX treatment. Symptoms may include chest tightness, headaches, abdominal pain, lightheadedness, flu-like symptoms, shivering, flushing, rash, and hypertension.

Monitor patients for signs or symptoms of hypersensitivity and infusion-related reaction throughout the infusion period and for at least 3 hours after end of infusion. Do not infuse the product faster than 500 mL/hour .

In the event of hypersensitivity or infusion reaction during administration, the infusion may be slowed or stopped. If the infusion is stopped, restart at a slower rate when the symptoms have resolved. Consider treatment with a corticosteroid or antihistamine for management of the reaction .

Hepatotoxicity with elevated liver transaminase has occurred after HEMGENIX treatment due to intravenous administration of a liver-directed AAV vector . Transaminitis may be immune mediated and reduce the therapeutic efficacy of the AAV-vector based gene therapy.

Monitor ALT levels by testing weekly for 3 months and thereafter monthly for up to 1 year following administration of HEMGENIX to mitigate risk of immune-mediated hepatotoxicity and potential decrease in Factor IX activity. Investigate alternative causes of ALT and other transaminase elevations.

In case of increased ALT levels above the upper limit of normal or double baseline levels consider a course of corticosteroid, with a subsequent taper, along with Factor IX activity monitoring Monitor ALT until it returns to baseline, or until after completion of corticosteroid treatment or as clinically indicated.

In AAV-vector based gene therapies, preexisting neutralizing anti-AAV antibodies may impede transgene expression at desired therapeutic levels. …

Etranacogene Dezaparvovec side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of HEMGENIX was evaluated in two clinical studies (study 1 enrolled 3 patients and study 2 enrolled 54 patients). Both studies enrolled adult male patients with moderately severe or severe Hemophilia B (N = 57), who received a single intravenous dose of 2 × 1013 gc/kg body weight of HEMGENIX. Three patients in study 1 and 50 of 54 patients from study 2 completed the study-specific 5-year follow-up period.

No serious adverse reactions were reported . The most common adverse reactions observed in ≥5% of patients post-dose are listed in Table 4:

Adverse Reactions ≥5% | Patients (%) (N = 57)

Alanine aminotransferase increased | 23 (40%)

Headache | 10 (18%)

Blood creatine kinase increased | 24 (42%)

Flu-like symptoms | 8 (14%)

Infusion-related reactionsInfusion-related reaction: Symptoms occurred during and after infusion in 7 and 12 patients, respectively. Infusions were temporarily interrupted and resumed at a slower infusion rate after treatment with antihistamines and/or corticosteroids in 3 patients. Eleven patients recovered on the day of or day after infusion, and eight patients recovered within 8 days after infusion. …

About this medicine

HEMGENIX (etranacogene dezaparvovec-drlb) is an adeno-associated viral vector-based gene therapy for intravenous infusion after dilution. HEMGENIX is a non-replicating recombinant AAV5 containing a codon-optimized DNA sequence of the gain-of-function Padua variant of human Factor IX (variant R338L), under control of a liver-specific promotor 1 (LP1).

HEMGENIX has a nominal concentration of 1 × 1013 gc/mL. Each vial contains an extractable volume of no less than 10 mL of HEMGENIX and the following excipients: sucrose (50 mg/mL), polysorbate-20 (0.22 mg/mL), potassium chloride (0.2 mg/mL), potassium phosphate (0.2 mg/mL), sodium chloride (8 mg/mL), and sodium phosphate (1.2 mg/mL).

HEMGENIX is sterile, clear and colorless suspension, and contains no preservative. After dilution, HEMGENIX should be clear and colorless suspension.

How it works: HEMGENIX is an adeno-associated virus serotype 5 (AAV5) based gene therapy designed to deliver a copy of a gene encoding the Padua variant of human coagulation Factor IX (hFIX-Padua). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 35b2db65-4c6c-4173-ab56-b2bca69193bd. Read the full official label on DailyMed.